HomeCompareRGLS vs PLD

RGLS vs PLD: Dividend Comparison 2026

RGLS yields 24.51% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $5.81M in total portfolio value· pulled ahead in Year 6
10 years
RGLS
RGLS
● Live price
24.51%
Share price
$8.16
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$95.9K
Annual income
$10,627.09
Full RGLS calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — RGLS vs PLD

📍 PLD pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRGLSPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RGLS + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RGLS pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RGLS
Annual income on $10K today (after 15% tax)
$2,083.33/yr
After 10yr DRIP, annual income (after tax)
$9,033.03/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, PLD beats the other by $4,029,083.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RGLS + PLD for your $10,000?

RGLS: 50%PLD: 50%
100% PLD50/50100% RGLS
Portfolio after 10yr
$3.00M
Annual income
$2,380,676.14/yr
Blended yield
79.30%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

RGLS
Analyst Ratings
9
Buy
9
Hold
Consensus: Buy
Price Target
$7.00
-14.2% upside vs current
Range: $7.00 — $7.00
Altman Z
46.8
Piotroski
1/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RGLS buys
0
PLD buys
0
No recent congressional trades found for RGLS or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRGLSPLD
Forward yield24.51%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$95.9K$5.91M
Annual income after 10y$10,627.09$4,750,725.19
Total dividends collected$60.2K$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$7.00$136.00

Year-by-year: RGLS vs PLD ($10,000, DRIP)

YearRGLS PortfolioRGLS Income/yrPLD PortfolioPLD Income/yrGap
1$13,151$2,450.98$11,241$540.96+$1.9KRGLS
2$17,084$3,012.41$13,019$991.13+$4.1KRGLS
3$21,937$3,657.30$15,801$1,870.97+$6.1KRGLS
4$27,862$4,389.03$20,609$3,701.21+$7.3KRGLS
5$35,022$5,209.71$29,919$7,867.97+$5.1KRGLS
6← crossover$43,593$6,120.11$50,631$18,617.74$7.0KPLD
7$53,765$7,119.64$105,528$51,352.20$51.8KPLD
8$65,734$8,206.35$287,364$174,449.42$221.6KPLD
9$79,713$9,376.98$1,081,760$774,280.77$1.00MPLD
10$95,920$10,627.09$5,908,209$4,750,725.19$5.81MPLD

RGLS vs PLD: Complete Analysis 2026

RGLSStock

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Full RGLS Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this RGLS vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RGLS vs SCHDRGLS vs JEPIRGLS vs ORGLS vs KORGLS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.